Clinical Trial Update: Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating retreatment with an EGFR tyrosine kinase inhibitor in EGFR mutation–positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Korea University Guro Hospital | Conditions: EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN